PMID- 23945305
OWN - NLM
STAT- MEDLINE
DCOM- 20140501
LR  - 20211203
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 52
IP  - 5
DP  - 2013 May
TI  - [The immunological effect of anti-leukemic tumor induced by eosinophilic 
      granulocyte].
PG  - 395-9
AB  - OBJECTIVE: To investigate the biological effect of anti-leukemic cells induced by 
      eosinophilic granulocyte (EOS) in bone marrow of patients with chronic 
      myelogenous leukemia (CML). METHODS: The BCR-ABL fusion gene as well as the 
      expression of IL-12 and IL-17 mRNA were performed by RT-PCR. The serum 
      concentrations of cytokine IL-12 and IL-17 were determined by enzyme-linked 
      immuno sorbent assay (ELISA). Immunochemistry staining and cytochemistry staining 
      were used to observe the peroxidase (POX) and human leukocyte antigen (HLA)-DR 
      expression of EOS in bone marrow. Immunofluorescence staining was used to observe 
      mannose receptor (MR), IL-12, IL-17A and IL-17 receptor A (IL-17RA) expression of 
      EOS. The results between the CML patients and the healthy controls were compared. 
      RESULT: Serum levels of IL-12 and IL-17 were higher in the 60 CML patients 
      [(196.33 +/- 21.79) ng/L and (36.55 +/- 3.01) ng/L] than those in the controls 
      [(96.60 +/- 4.92) ng/L and (23.74 +/- 1.36) ng/L]. In the 32 patients with activated 
      EOS, the levels of IL-12 and IL-17 were (273.12 +/- 17.16) ng/L and (40.11 +/- 6.13) 
      ng/L, which were significantly higher than those in the non-activated EOS 
      [(126.16 +/- 14.27) ng/L and (28.14 +/- 5.29) ng/L] (P values < 0.01). IL-12 and 
      IL-17 mRNA were expressed in activated EOS, while BCR-ABL fusion gene was not 
      found. The amounts of EOS were increased abnormally in the bone marrow and 
      peripheral blood of the CML patients with POX positive staining in the cytoplasm 
      and weakly positive HLA-DR staining. It was observed easily by a microscope that 
      EOS could attack leukemic cells in bone marrow through adhesion, capture and 
      phagocytosis. Activated EOS could express IL-12, IL-17A and MR, which was related 
      with the serum levels of these cytokines. CONCLUSIONS: Activated EOS in bone 
      marrow of CML patients could express IL-12 and IL-17. Activated EOS could induce 
      coup injury to leukemic cell by releasing POX and expressing IL-12 and IL-17. It 
      can also capture or swallow target cells via the expression of MR on the 
      membrane. EOS may play an important role in the anti-tumor immunologic function 
      in bone marrow of CML patients.
FAU - Sun, Li-fei
AU  - Sun LF
AD  - Department of Tumor Research and Treatment Centricity, the 148th Hospital of PLA, 
      Zibo, Shandong Province 255300, China. sunlifei_2007@163.com
FAU - Wu, Qiang-qiang
AU  - Wu QQ
FAU - Hao, Hong-feng
AU  - Hao HF
FAU - Ma, Xiang-shan
AU  - Ma XS
FAU - Du, Yan-hui
AU  - Du YH
FAU - Wang, Gui-chen
AU  - Wang GC
FAU - Zhang, Jin-biao
AU  - Zhang JB
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 0 (Interleukin-17)
RN  - 0 (Lectins, C-Type)
RN  - 0 (Mannose Receptor)
RN  - 0 (Mannose-Binding Lectins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Cell Surface)
RN  - 187348-17-0 (Interleukin-12)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Adult
MH  - Case-Control Studies
MH  - Eosinophils/*immunology
MH  - Female
MH  - Fusion Proteins, bcr-abl/genetics/metabolism
MH  - Humans
MH  - Interleukin-12/genetics/metabolism
MH  - Interleukin-17/genetics/metabolism
MH  - Lectins, C-Type/metabolism
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*immunology/metabolism
MH  - Male
MH  - Mannose Receptor
MH  - Mannose-Binding Lectins/metabolism
MH  - Middle Aged
MH  - Peroxidase/metabolism
MH  - RNA, Messenger/genetics
MH  - Receptors, Cell Surface/metabolism
EDAT- 2013/08/16 06:00
MHDA- 2014/05/03 06:00
CRDT- 2013/08/16 06:00
PHST- 2013/08/16 06:00 [entrez]
PHST- 2013/08/16 06:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2013 May;52(5):395-9.